10. Nelson WH, Sullivan P, Khan A and Tamragouri RN
The effects of age on dexamethasone suppression test results in alcoholic patients.
American Journal of Psychiatry 143(2): 237-239, February 1986
11. Khan A, Lee E, Dager S, Hyde T, Raisys V, Avery D, Dunner DL
Platelets MAO activity in anxiety and depression.
Biological Psychiatry 21(8-9): 847-849, July 1986
12. Dager S, Khan A, Comess K, Raisys V and Dunner DL
Mitral valve abnormalities and catecholamine activity in anxious patients.
Psychiatry Research 20: 13-18, 1987.
13. Khan A, Cohen S, Chiles J, Stowell M, Hyde T and Robbins M
Therapeutic role of a psychiatric intensive care unit in acute psychosis.
Comprehensive Psychiatry 28(3): 264-269, June 1987
14. Dunner DL, Myers J, Khan A, Avery D, Ishiki D and Pyke R
Adinazolam - a new antidepressant: findings of a placebo controlled, double-blind study in outpatients with major depression.
Journal of Clinical Psychopharmacology 7(3): 170-172, June 1987
15. Khan A, Cohen S, Stowell M, Capwell R, Avery D and Dunner DL
Treatment options in severe psychotic depression.
Convulsive Therapy 3(2): 93-99, 1987
16. Cohen S, Khan A and Johnson S.
Pharmacological management of manic psychosis in an unlocked setting.
Journal of Clinical Psychopharmacology 7(4): 261-264, August 1987
17. Cohen S and Khan A
Adjunctive benzodiazepines in acute schizophrenia.
Neuropsychobiology 18: 9-12, 1987
18. Cohen S and Khan A
Respiratory distress with use of lorazepam in mania.
Journal of Clinical Psychopharmacology 7(3): 199-200, June 1987
19. Geiduschek J, Cohen S, Khan A and Cullen BF.
Repeated anesthesia for a patient with neuroleptic malignant syndrome.
Anesthesiology 68: 134-137, 1988
20. Scher M, Hartford J, Khan A, Gentry R and Wilson L.
Comparison of two formats for a psychiatry clerkship.
Journal of Medical Education 63(2): 140-143, February 1988
21. Solan W, Khan A, Avery D and Cohen S.
Psychotic and nonpsychotic depression: comparison of response to ECT.
Journal of Clinical Psychiatry 49(3): 97-99, 1988
22. Cohen S, Khan A, Clark A, Goldner M and Dunner DL.
Hospitalization effect in acute mania.
General Hospital Psychiatry 10(2): 138-141, March 1988
23. Cohen S, Khan A and Robison J.
Significance of mixed features in acute mania.
Comprehensive Psychiatry 29(4): 421-426, August 1988
24. Khan A, Johnson F, Avery D, Cohen S, Scherzo B and Dunner DL
DST results in nonpsychotic depressed outpatients. [abstract here]
American Journal of Psychiatry 145(9): 1153-1156, September 1988
25. Khan A, Cohen S, Dager S, Avery D and Dunner DL.
Onset of response in relation to outcome in depressed outpatients with placebo and imipramines. [abstract here]
Journal of Affective Disorders 17(1): 33-38, August 1989
26. Cohen S, Khan A and Cox G.
Demographic and clinical features predictive of recovery in acute mania.
The Journal of Nervous and Mental Disease 177(10): 638-642, October 1989
27. Khan A, McMurray JS, McCreery JM and Hunt H
Carbamazepine and SIADH.
American Journal of Psychiatry 146(12): 1639, December 1989
28. Vitiello MV, Prinz PN, Avery DH, Williams DE, Ries RK, Bokan JA and Khan A
Sleep is undisturbed in elderly, depressed individuals who have not sought health care.
Biological Psychiatry 27 (4): 431-440, February 1990
29. Scher M, Briggs T, Khan A and Cohen S
Patient satisfaction with care received in teaching settings
Academic Psychiatry 12: 21-26, 1990.
30. Cohen S and Khan A
The antipsychotic effect of milieu in the acute treatment of schizophrenia.
General Hospital Psychiatry 12 (4): 248-251, July 1990
31. Healey W, Khan A and Noonan C
Major depression with psychosis (MD-P): demographic, phenomenological, and outcome characteristics in one hospitalized population.
Journal of Nervous and Mental Disease 178: 722-723, 1990
32. Dager SR, Khan A, Cowley D, Avery DH, Elder J, Roy-Byrne P and Dunner DL
Characteristics of placebo response during long-term treatment of panic disorder. [abstract here]
Psychopharmacology Bulletin 26 (3): 273-278, 1990
33. Avery DH, Khan A, Dager SR, Cox G and Dunner DL
Bright light treatment of winter depression: morning versus evening light.
Acta Psychiatrica Scandinavica 82: 335-338, 1990
34. Avery DH, Khan A, Dager SR, Cohen S, Cox GB and Dunner DL
Morning or evening bright light treatment of winter depression? The significance of hypersomnia.
Biological Psychiatry 29: 117-126, 1991
35. Avery D, Khan A, Dager S, Cohen S, Cox G and Dunner DL
Is morning light exposure superior to evening light in treating seasonal affective disorder?
Psychopharmacology Bulletin 26 (4): 521-524, 1990
36. Khan A, Dager S, Cohen S, Avery D, Scherzo B and Dunner DL
The chronicity of depressive episode in relation to antidepressant-placebo response. [abstract here]
Neuropsychopharmacology 4: 125-130, 1991
37. Cohen S, Khan A, Zheng Y and Chiles J
Tardive dyskinesis in the mentally retarded: comparison of prevalence, risk factors and topography with a schizophrenic population.
Acta Psychiatrica Scandinavica 83: 234-237, 1991
38. Khan A, Fabre L and Rudolph R
Psychopharmacology Bulletin 27 (2): 141-144, 1991
39. Khan A and Brown WA
Who should receive antidepressants: suggestions from placebo treatment.
Psychopharmacology Bulletin 27 (3): 271-274, 1991
40. Khan A, Noonan C and Healey W
Is a single tricyclic antidepressant trial an active treatment for psychotic depression?
Progress in Neuropsychopharmacology and Biological Psychiatry 15 (6): 765-770, 1991
41. Khan A, Shim H, Mirolo MH, Horita A, Douglas R and Tucker GJ
TRH effects on arousal, locomotor activity and spontaneous alternation in ECS post-ictal state.
Psychopharmacology 106: 570-571, 1992
42. Davis JM, Janicak PG and Khan A
Neuroleptic Malignant Syndrome.
In: Dunner DL, ed., Current Psychiatric Therapy, WB Saunders, Philadelphia, Pennsylvania, 170-175, 1992
43. Goren A, Swindell C and Khan A
Expressive language characteristics of schizophrenic subjects with different medication histories.
Journal of Neurolinguistics 7: 67-90, 1992
44. Khan A, Mirolo HA and Mirolo MH
Depression in the elderly: A treatable disorder
Geriatrics 48(suppl 1): 14-17, 1993
45. Khan A, Mirolo MH, Claypoole K and Hughes D
Low dose TRH effects in cognitively impaired alcoholics.
Alcoholism: Clinical and Experimental Research 17(4): 791-796, August, 1993
46. Khan A, Mirolo MH, Hughes D and Bierut L
Electroconvulsive Therapy.
Psychiatric Clinics of North America 16 (3): 497-513, September 1993
47. Khan A, Mirolo MH, Mirolo HA and Miller S
Can ECT-induced cognitive effects be altered pharmacologically?
Progress in Neuropsychopharmacology and Biological Psychiatry 17: 861-874, 1993
48. Khan A, Mirolo MH, Lai H, Claypoole K, Bierut L, Malik R, and Bhang J
ECT and TRH: Cholinergic Involement in a Cognitive Deficit State.
Psychopharmacology Bulletin 29 (3): 345-352, 1993
49. Khan A, Lai H, Ukai Y and Mirolo MH
NS-3, a TRH-Analog, Reverses Repeated ECS- Induced Deficits in Water-Maze Performance in the Rat.
Pharmacology, Biochemistry and Behavior 47 (3): 477-481, 1994
50. Brown WA and Khan A
Which Depressed Patients Should Receive Antidepressants?
CNS Drugs 1 (5): 341-347, 1994
51. Rosenfarb IS, Becker J, and Khan A
Perceptions of parental and peer attachments by women with mood disorders. Journal of Abnormal Psychology 103 (4): 637-644, 1994.
52. Khan A, Mirolo MH, Claypoole K, Bhang J, Cox G, Horita A and Tucker GJ
Effects of low-dose TRH in the ECT post-ictal state.
American Journal of Psychiatry 151 (11): 1694-1696, November 1994
53. Rosenfarb IS, Becker J, Khan A, and Mintz J
Dependency, self-criticism and perceptions of socialization experiences.
Journal of Abnormal Psychology 103 (4): 669-675, 1994
54. Khan A, Lai H, Nishimura Y, Mirolo MH, and Singh NP
Effect of ECS on DNA single- strand breaks in rat brain cells.
Convulsive Therapy 11 (2): 114-121, June 1995
55. Singh NP and Khan A
Acetaldehyde: geno- and cytotoxicity in human lymphocytes.
Mutation Research 337: 9-17, 1995
56. Khan A, Rudolph R, Baumel B, Ferguson J, Ryan PJ, and Shrivatsava R
Venlafaxine in depressed geriatric outpatients: an open-label clinical study.
Psychopharmacology Bulletin 31 (4): 753-758, 1995
57. Singh NP, Graham, MM, Singh V, and Khan A
Induction of DNA single-strand breaks in human lymphocytes by low doses of gamma rays.
International Journal of Radiation Biology 68 (5): 563-569, 1995
59. Singh NP, Lai H, and Khan A
Ethanol-induced single-strand DNA breaks in rat brain cells.
Mutation Research 345 (3-4): 191-196, December 1995
60. Khan A
Overall safety profile of venlafaxine: a commentary.
Journal of Clinical Psychopharmacology 16 (suppl 2): 59S-61S, June 1996
61. Chandos B, Khan A, Lai H and Lin JC
(E Ueno, edi)The application of electromagnetic energy to the treatment of neurological and psychiatric diseases.
In Biological effects of magnetic and electromagnetic fields, Plenum Press, NY, pp.161-169, 1996
62. Khan A
Letter to the Editor (Antidepressant Discontinuation Syndrome)
Psychiatric Annals 27: 259, April, 1997
63. Lehman AK, Ellis B, Becker J, Rosenfarb I, Devine R, Khan A and Reichler R
Personality and depression: a validation study of the depressive experiences questionnaire.
Journal of Personality Assessment 68 (1): 197-210, February 1997
64. Khan A, Upton, GV, Rudolph R, Entsuah R, Leventer SM and venlafaxine investigator study group
The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: A dose-response study.
Journal of Clinical Psychopharmacology 18 (1): 19-25, February 1998
65. Rosenfarb IS, Becker J, Khan A, Mintz J
Dependency and self-criticism in bipolar and unipolar depressed women.
British Journal of Clinical Psychology 37: 409-414, November 1998
66. Khan A
Treating Depression.
Psychiatric Annals 29 (3): 123-124, March 1999
67. Khan A, Warner H, and Brown, WA
Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the FDA database.
Archives of General Psychiatry 57: 311-317, April 2000
Invited Commentaries by Drs. Leber, Michels, Quitkin, Klein, Hirschfeld, Chmura Kramer, Leon. Archives of General Psychiatry 57: 319-330, 2000
Cited in New York Times. Erica Goode. More fuel for debate on Prozac. OL.CXLIX, No. 51; 369, Tuesday, April 25, 2000
Cited in Science. Martin Enserink. Are placebo-controlled drug trials ethical? Science 288: 5465, April 21, 2000, p. 416.
Cited in WebMD. Amy Rothman Schonfeld. Analysis of FDA data indicates placebo-treated patients not at increased risk for suicide compared with active controls-experts debate the role of placebo-controlled trials. April 17, 2000.
Cited in Science News. Bruce Bower. Placebos for depression attract scrutiny, 157: April 29, 2000, p.278.
68 A. Cohen S, Glazewski R, Khan S, and Khan A
Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.
Journal of Clinical Psychiatry 62 (2): 114-116, February 2001
68. Khan A and Brown WA
Placebo enigma in antidepressant clinical trials.
Invited Guest Editorial. Journal of Clinical Psychopharmacology 21(2): 123-125, 2001
69. Khan A, Khan S, Leventhal R and Brown W
Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the FDA database.
International Journal of Neurpsychopharmacology 4: 113-118, 2001
70. Khan A, Khan S, Leventhal R, and Brown WA
Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the FDA database.
American Journal of Psychiatry 158 (9): 1449-1454, 2001
71. Khan A, Leventhal S, Khan S, and Brown WA
Severity of depression and response to Antidepressants and placebo: An analysis of the FDA database.
Journal of Clinical Psychopharmacology 22(1): 40-45, 2002
72. Khan A, Leventhal R, Khan S and Brown WA
Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database.
Journal of Affective Disorders 68: 183-190, April 2002
73. Khan A, Khan S, Leventhal R, Krishnan R, and Gorman J
An application of the revised CONSORT standards to FDA summary reports of recently approved antidepressants and antipsychotics.
Biological Psychiatry 52 (1): 62-67, July 2002
74. Khan A and Leventhal R
Medical aspects of capital punishment executions.
Journal of Forensic Science 47 (4): 847-851, July 2002
75. Cohen S, Fitzgerald B, Okos A, Khan S, Khan A
Weight, lipid, glucose and behavioral measures with ziprasidone treatment in a population with mental retardation.
Journal of Clinical Psychiatry 64 (1): 60-62, January 2003
76. Khan A, Khan S, Brown WA
Are placebo controls necessary to test new antidepressants and anxiolytics?
International Journal of Neuropsychopharmacology 5: 193-197, September 2002
77. Khan A, Khan SR, Shankles EB, Polissar NL
elative sensitivity of the Montgomery-Asberg Depression rating Scale, the Hamilton Depression rating Scale and the Clinical Global Impressions rating scale in antidepressant clinical trials.
International Clinical Psychopharmacology 17 (6): 281-285, 2002
78. Khan A and Khan S
Placebo in mood disorders: the tail that wags the dog.
Current Opinion in Psychiatry 16: 35-39, January 2003
79. Khan A, Khan SR, Walens G, Kolts R and Giller EL
Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: An analysis of the Food and Drug Administration Summary Basis of Approval reports.
Neuropsychopharmacology 28: 552-557, March 2003
80. Khan A, Detke M, Khan S and Mallenkrodt C
Placebo response and antidepressant clinical trial outcomes.
Journal of Nervous and Mental Disease 19 (4): 211-218, April 2003
81. Khan A, Khan S, Kolts R, Brown WA
Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: Analysis of FDA reports.
American Journal of Psychiatry 160 (4): 790-792, April 2003
82. Storosum J, van Zweiten B, Wohlfarth T, de Haan L, Khan A, van der Brink W
Suicide risk in placebo versus active treatment in placebo-controlled trials for schizophrenia.
Archives of General Psychiatry 60(4): 365-368, April 2003
83. Cohen SA, Fitzgerald BJ, Khan S, Khan A
The effect of a switch to Ziprasidone in an adult population with autistic disorder: Chart review of naturalistic, open-label treatment.
Journal of Clinical Psychiatry 65 (1): 110-113, January 2004
84. Robinson D and Khan A
Dosing strategies for antidepressant clinical trials: A commentary (Editorial).
Journal of Clinical Psychopharmacology 24(1): 1-3, Feb 2004
85. Khan A, Brodhead AE, Kolts RL
Relative sensitivity of the Montgomery-Asberg Depression rating Scale, the Hamilton Depression rating Scale and the Clinical Global Impressions rating scale in antidepressant clinical trials.
International Clinical Psychopharmacology 19: 157-160, May 2004
86. Rickels K, Mangano R, Khan A
A double-blind, placebo-controlled study of a flexible dose of Venlafaxine ER in adult outpatients with generalized social anxiety disorder.
Journal of Clinical Psychopharmacology 24 (5): 488-496, October 2004
87. Khan A, Kolts RL, Thase ME, Krishnan KR, Brown WA
Research design features and patient characteristics associated with antidepressant clinical trial outcome.
American Journal of Psychiatry, 160 (11): 2045-2049, November 2004
88. Khan A, Ginsberg LD, Asnis GM, Goodwin FK, Davis KH, Kishnan AA
Effect of Lamotrigine on cognitive complaints in patients with bipolar I disorder.
Journal of Clincial Psychiatry, 65 (11): 1483-1490, November 2004
89. Labellarte M, Biederman J, Emslie G, Ferguson J, Khan A, Ruckle J, Sallee R, Riddle M
Multiple-Dose Pharmacokinetics of Fluvoxamine in Children and Adolescents.
Journal of the American Academy of Child and Adolescent Psychiatry, 43 (12): 1497 – 1505, December 2004
90. Khan A, Brodhead AE, Kolts RL, Brown WA
Severity of depressive symptoms and response to antidepressants and placebo in antidepressant clinical trials.
Journal of Psychiatric Research, 39 (2): 145-150, March 2005
91. Khan A, Kolts RL, Rapaport MH, Krishan KR, Brodhead AE, Brown WA
Magnitude of placebo response and drug placebo differences across psychiatric disorders.
Psychological Medicine, 35(5): 743-749, May 2005
92. Khan A, Schwartz K
Study designs and outcome in antidepressant clinical trials.
Essential Psychopharmacology, 6(4): 221 – 226, 2005
93. Khan A, Brodhead AE, Schwartz KA, Kolts RL, Brown WA
Sex differences in antidepressant response among outpatients participating in antidepressant clinical trials.
Journal of Clinical Psychopharmacology, 25(4): 318-324, August 2005
Cited in Consumer Reports on Health. Drug Safety: His and Hers. December 2005
94. Khan A, Schwartz K
Design features that affect psychopharmacology trials.
Letters in Drug Design & Disocvery, 2 (7) 546-550, November 2005
95. DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G
Mifepristone vs Placebo in the Treatment of Psychosis in Patients with Psychotic Major Depression.
Biological Psychiatry, 60(12) 1343-9, December 2006, Epub 2006 Aug 4
96. Khan A, Brodhead AE
Fixed and flexible dosing strategies among antidepressant clinical trials. Electronic Version www.siicsalud.com (ISSN: 1667-9008), Section “Expert Invitados,” “Expertos del Mundo.” Published as from April 2004 URL http://wwwsiicsalud.com/dato/buscador/05527000.htm
Journal Version. Salud Mental, ISSN 1667-9105, 9(1), 4-5, September 2005
97. Khan A, Kolts RL, Brodhead AE, Krishnan KR, Brown WA
Suicide risk analysis among patients assigned to psychotropics and placebo.
Psychopharmacology Bulletin, 39(1): 6-14, 2006
98. Khan A, Stern C
Design features, patient characteristics associated with antidepressant clinical trial outome.
99. Khan A, Schwartz KA, Kolts RL, Brown W
BMI, sex, and antidepressant response.
Journal of Affective Disorders, 99(1-3): 101-106, 2007
100. Khan A, Schwartz K, Kolts RL, Ridgway D, Lineberry C
Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.
Biological Psychiatry, 62(1): 65-71, 2007.
101. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese J, BOLDER II Study Group
Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study).
Journal of Clinical Psychopharmacology, 26(6): 600-609, 2006.
102. Khan A, Schwartz K
Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA Summary Basis of Approval reports. Annals of Clinical Psychiatry, 19(1): 1-6, 2007.
103. Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E
Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release.
Journal of Clinical Psychiatry, 68(1): 58-68, 2007.
104. Lindenmayer JP, Khan A, Eerdekens M, Van Hove I, Kushner S
Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.
European Neuropsychopharmacol, 17 (2): 138-44, 2007; Epub 2006 Oct 17
105. Alper K, Schwartz KA, Kolts RL, Khan A
Seizure risk incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.
Biological Psychiatry, 62(4):345-54, 2007; Epub 2007 Jan 16
106. Khan A, Schwartz, K, Kolts RL, Redding N, Brown, WA
Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports.
Neuropsychopharmacology, 32(11):2422-30, 2007; Epub 2007 Feb 21
107. Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C.
Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Clinical Drug Investigation, 27(7): 481-492., 2007
108. Thase ME, Shelton RC, Khan A
Treatment of SSRI nonresponders with venlafaxine extended release: a randomized comparison of standard and higher dosing strategies.
Journal of Clinical Psychopharmacology, 26(3):250-258, 2006
109. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Journal of Clinical Psychiatry, 68(6):843-853, 2007
110. Khan A, Schwartz K, Stern C, Redding N, Kolts RL, Brown WA, Robinson D
Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials.
Journal of Clinical Psychiatry, 68(12):1828-1833, 2007
111. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus N, Owen R
Aripiprazole monotherapy in non-psychotic bipolar I depression: results of two randomized, placebo-controlled studies.
Journal of Clinical Psychopharmacology 28(1) 13-20, 2008
112. Ridgway D, Khan A, Ridgway G, Cierpial MA, Linebery CG
Subject numbers and placebo outcome variability in clinical trials of new CNS medications.
Drug Information Journal, 41: 701-709, 2007
113. Khan A, Redding N, Brown WA
The persistence of the placebo response in antidepressant clinical trials.
Journal of Psychiatric Research,42: 791-796, 2008
114. Nelson JC, Thase ME, Khan A
Are antidepressants effective? What’s a Clinician to think?
J Clin Psychiatry 69:1014-1015, 2008
115. Khan A, Khan S
Placebo response in depression : A perspective for clinical practice.
Psychopharmacology Bulletin 41(3) 91-98, 2008
116. Khan A
Current evidence for aripiprazole as augmentation therapy in major depressive Disorder
Exp Rev Neurother 8 (10): 1435-1447, 2008
117. Gelenberg A, Thase M, Meyer R, Goodwin F, Katz M, Kraemer H, Potter W, Shelton R, Fava M, Khan A et al.
The history and current state of antidepressant clinical trial design: a call to action for proof – of – concept studies.
J Clin Psychiatry 69:1513-1528, 2008
118. Khan A, Bhat A
Is the problem of a high placebo response unique to antidepressant trials?
J Clin Psychiatry 69:1979-1980, 2008